Delivering N-acetylcysteine directly to the brain to help treat Parkinson's Disease
Official title: Circumventing the pharmacokinetic/pharmacodynamic limitations of antioxidant therapy for Parkinson's Disease by nose to brain delivery of N-acetylcysteine
Funded at Neuronasal INC · NIH-10920628 · Data updated 2026-11-12
This study is exploring a new way to deliver a helpful antioxidant called N-acetylcysteine (NAC) directly to the brain to see if it can help slow down Parkinson's Disease, and it's designed for people living with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neuronasal INC NIH-funded |
| Lab location | 1 site (Wexford, United States) |
| Project start | September 25, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $478,165 |
| NIH project number | 1R41AG087860-01 |
| Project ID | NIH-10920628 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Parkinson's Disease, particularly those experiencing early to moderate symptoms.
✕Less likely to help
Patients with advanced Parkinson's Disease or those who do not respond to antioxidant therapies may not benefit from this research.
What this research studies
This research investigates a new method of delivering N-acetylcysteine (NAC), an antioxidant, directly to the brain to potentially slow the progression of Parkinson's Disease (PD). The approach aims to overcome the limitations of traditional NAC delivery methods, which may not effectively reach the brain. By using a nose-to-brain delivery system, the study seeks to enhance the bioavailability of NAC, targeting the neurodegenerative processes associated with PD. Patients with PD may benefit from this innovative treatment strategy that focuses on neuroprotection.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that may slow down the progression of Parkinson's Disease and improve patients' quality of life.
How similar studies have gone: While the use of NAC has been studied in various contexts, this specific nose-to-brain delivery method is novel and has not been extensively tested in Parkinson's Disease.
Where this research is happening
-
Neuronasal INC
Wexford, United States Active
Researchers
- Principal investigator: Greene, Douglas — Neuronasal INC
- Study coordinator: Greene, Douglas
Related research
Other NIH-funded projects on the same topics.
-
Gut-brain clues in Parkinson’s disease: supplement to a large registry
A plant-wide supplement to an NIH program will enroll people with Parkinson’s, with and without GI symptoms, plus healthy controls, to study how gut function, brain signals, and sleep rhythms relate to Parkinson’s symptoms.
-
Gut-brain connections in Parkinson’s disease: how the gut and environment shape symptoms
A Mayo Clinic team is studying how gut problems, environmental factors, and genetics together influence Parkinson’s disease and its GI symptoms to find biomarkers and better understanding of the disease.
-
Gut-brain communication in Parkinson’s disease for better symptoms and daily life
This project enrolls people with Parkinson’s disease and healthy controls to build a big registry and study how gut function, brain signals, sleep, and circadian rhythms relate to PD symptoms.
-
Gut microbiome and Parkinson's disease: how gut bugs relate to symptoms and progression
A multi-year study will look at gut bacteria and related markers in people with Parkinson’s disease to understand how the gut-brain connection may influence symptoms and progression.
-
Gut-Brain Axis in Parkinson’s Disease: biomarkers and procedures to track progression
A patient-focused program to study how gut health and the brain interact in Parkinson’s disease using biomarkers and clinical procedures.
-
Understanding posture and movement in Parkinson’s patients to reduce falls
A study using wearable sensors to track real-world balance and movement in people with Parkinson’s disease to help prevent falls.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.